Low IGFBP7 expression identifies a subset of breast cancers with favorable prognosis and sensitivity to IGF-1 receptor targeting with ganitumab: Data from I-SPY2 and SCAN-B

Christopher Godina; Michael N Pollak; Helena Jernström

doi:10.1101/2023.12.18.23300129

Abstract

There has been a long-standing interest in targeting the insulin-like growth factor-1 receptor (IGF-1R) signaling system in breast cancer due to its key role in neoplastic proliferation and survival. However, no IGF-1R targeting agent has shown substantial clinical benefit in controlled trials, and no treatment predictive biomarkers for IGF-1R targeting agents exist. IGFBP7 is an atypical insulin-like growth factor binding protein as it has a higher affinity for the IGF-1R than IGF ligands. We report that low IGFBP7 gene expression identifies a subset of breast cancers for which the addition of ganitumab (an anti-IGF-1R monoclonal antibody) to chemotherapy substantially improved the pathological complete response rate compared to neoadjuvant chemotherapy alone. Furthermore, high IGFBP7 expression predicted increased distant metastasis risk. If our findings are confirmed, decisions to halt the development of IGF-1 targeting drugs, which were based on disappointing results of prior trials that did not use predictive biomarkers, should be reviewed.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT01042379 and NCT02306096

Funding Statement

This study was funded by the Swedish Cancer Society (CAN 20 0763 and CAN 23 2952), the Faculty of Medicine at Lund University, the Mrs Berta Kamprad Foundation, and the South Swedish Health Care Region (Region Skane ALF 40620). Dr. Pollak acknowledges funding from the Terry Fox Foundation. The funders had no role in study design and conduct of the study, data collection and analysis, data interpretation, or manuscript preparation and decision to submit the manuscript for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Clinical and RNA-seq data from SCAN-B is accessible from Staaf et al. 21, available at Mendeley Data. The clinical and transcriptomic data from I-SPY2 are available from the GEO database (GSE194040). This paper does not report original code. Any additional information required to reanalyze the data reported in this paper is available upon request. 21 Staaf, J., et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer 8, 94 (2022).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

We have added a new figure (Figure 4) and new table (Table 1). We have also revised the main text somewhat.

Data Availability

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE194040

https://data.mendeley.com/datasets/yzxtxn4nmd/3

Abbreviations

DEGs: Differentially expressed genes
DGE: Differential gene expression
DMFI: Distant metastasis-free interval
ER: Estrogen receptor
EMT: Epithelial-mesenchymal transition
FC: Fold change
FDR: False discovery rate
FPKM: Fragments per kilobase of exon per million mapped reads
GEO: Gene Expression Omnibus
GEX: Gene expression profile
GSEA: Gene set enrichment analysis
HER2: Human epidermal growth factor receptor 2
HR: Hazard ratio
HR: Hormone receptor
IGF-1: Insulin-like growth factor-1 IGF-2 - Insulin-like growth factor-2
IGFBP7: Insulin-like growth factor receptor binding protein-7
IGF-1R: Insulin-like growth factor-1 receptor
I-SPY2: Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2
OR: Odds ratio
OS: Overall survival
pCR: pathological complete response
PR: Progesterone receptor
RFI: Recurrence-free interval
RNA-seq: Massive parallel paired-end sequencing of mRNA
SCAN-B: Swedish Cancerome Atlas Network - Breast
TME: Tumor microenvironment
TNBC: Triple-negative breast cancer
Q: Quartile

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.